中国临床药理学杂志2017，Vol.33Issue(22)：2226-2229,4.DOI:10.13699/j.cnki.1001-6821.2017.22.004
尼可地尔联合瑞舒伐他汀对经皮冠状动脉介入治疗患者的心肌保护作用
Protective effect of nicorandil combined with rosuvastatin on myocardial tissue in patients who underwent percutaneous coronary intervention
摘要
Abstract
Objective To explore the protective effect of nicorandil combined with rosuvastatin on myocardial tissue in patients who underwent percutaneous coronary intervention (PCI).Methods A total of 68 patients with coronary heart diseases (CHD) who underwent PCI were randomly divided into control group (36 cases) and treatment group (32 cases).The control group was treated with rosuvastatin 10 mg once daily for 3 d before PCI.The treatment group was given nicorandil 5 mg three times daily for 3 d before PCI on the basis of control group.Levels of serum high-sensitive troponin T (hs-cTnT),high-sensitive C-reactive protein (hs-CRP),tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10)were measured before PCI and 24,48 h after PCI.Results The markedly effective rates in treatment group and control group were 78.13％ (25/32),52.78％ (19/36),with significant difference (P ＜ 0.05).Before PCI,the levels of hs-cTnT in the treatment group and control group were (36.56 ± 15.35),(30.29 ± 13.67) pg · mL-1,hs-CRP were (3.67 ± 1.24),(3.53 ± 1.32) mg · L-1,TNF-α were (6.54 ± 2.42),(6.76 ±2.15)pg · mL-1,IL-10 were(6.87 ± 1.92),(7.02 ± 1.85)pg · mL-1.At 24 h after PCI,the levels of hs-cTnTwere(71.25 ± 17.87),(82.65 ± 18.34)pg · mL-1,hs-CRP were(9.48 ±2.35),(13.56 ±3.52) mg · L-1,TNF-α were(8.72 ± 2.26),(10.65 ± 3.16) pg· mL-1,IL-10 were (13.55 ± 4.51),(11.21 ± 3.54) pg · mL-1 At 48 h after PCI,the levels of hs-cTnT were(60.56 ± 15.64),(73.54 ± 16.51)pg · mL-1,hs-CRP were(6.62±1.98),(10.24±2.84)mg· L-1,TNF-α were(7.56±1.86),(8.86±1.95)pg· mL-1,IL-10 were(11.16 ± 3.28),(9.76 ± 3.11) pg · mL-1,and the differences of all the parameters above between the two groups were statistically significant (P ＜ 0.05).No adverse drug reactions were found in both groups.Conclusion Nicorandil combined with rosuvastatin before PCI is able to reduce inflammatory factors,improve the level of IL-10 and alleviate myocardial injury,with high safety profile.关键词
尼可地尔/瑞舒伐他汀/冠心病/经皮冠状动脉介入治疗术/心肌保护Key words
nicorandil/rosuvastatin/coronary heart disease/percutaneous coronary intervention/myocardial protection分类
医药卫生引用本文复制引用
李娟,莫凡睿,颜玉鸾,赖沙毅,楚罗湘..尼可地尔联合瑞舒伐他汀对经皮冠状动脉介入治疗患者的心肌保护作用[J].中国临床药理学杂志,2017,33(22):2226-2229,4.基金项目
国家自然科学基金资助项目(81160030) （81160030）
广西区卫计委基金资助项目(Z2015141) （Z2015141）
